Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.
Liu, C., Lin, J., Moslin, R., Tokarski, J.S., Muckelbauer, J., Chang, C., Tredup, J., Xie, D., Park, H., Li, P., Wu, D.R., Strnad, J., Zupa-Fernandez, A., Cheng, L., Chaudhry, C., Chen, J., Chen, C., Sun, H., Elzinga, P., D'arienzo, C., Gillooly, K., Taylor, T.L., McIntyre, K.W., Salter-Cid, L., Lombardo, L.J., Carter, P.H., Aranibar, N., Burke, J.R., Weinstein, D.S.(2019) ACS Med Chem Lett 10: 383-388
- PubMed: 30891145 
- DOI: 10.1021/acsmedchemlett.9b00035
- Primary Citation of Related Structures:  
6NSL - PubMed Abstract: 
In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo- N 1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2- b ]pyridazine analogs were found to display dramatically improved metabolic stability ...